Thrombotic events associated with megestrol acetate in patients with AIDS cachexia

Nutrition

Volumn 15, Issue 4, 1999, Pages 294-298

  Koller, Elizabeth ^a   Gibert, Cynthia ^b   Green, Lanh ^a   Mann, Marianne ^a   Bernstein, Barry ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Veterans Affairs Center   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL ACETATE; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTICOAGULATION; ARTICLE; CACHEXIA; CASE REPORT; DEEP VEIN THROMBOSIS; ECHOGRAPHY; HUMAN; LUNG SCINTISCANNING; MALE; PHLEBOGRAPHY; PLETHYSMOGRAPHY; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; APPETITE STIMULANTS; CACHEXIA; CD4 LYMPHOCYTE COUNT; HUMANS; MALE; MEGESTROL ACETATE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; SEXUALLY TRANSMITTED DISEASES; VENOUS THROMBOSIS;

EID: 0032955902     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(99)00007-6     Document Type: Article

References (16)

1. Haller D.G., Glick J.H. Progestational agents in advanced breast cancer An overview . Semin Oncol. 13:1986;2.
2. Kneale B.L. Adjunctive and therapeutic progestins in endometrial cancer. Clin Obstet Gynaecol. 13:1986;789.
3. Loprinzi C.L., Ellison N.M., Schaid D.J., et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 82:1990;1127.
4. Loprinzi C.L., Johnson P.A., Jensen M. Megestrol acetate for anorexia and cachexia. Oncology. 49:1992;46.
5. Oster M.H., Enders S.R., Samuels S.J., et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 121:1994;400.
6. Von-Roenn J.H., Armstrong D., Kotler D.P., et al. Ann Intern Med. 121:1994;393.
7. Von-Roenn J.H. Randomized trials of megestrol for AIDS-associated anorexia and cachexia. Oncology. 51:(suppl 1):1994;19.
8. Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., MacRae K.D. Third generation oral contraceptives and risk of venous thrombotic disorders: an international case control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J. 312:1996;83.
9. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicenter case-control study. Lancet 1995;346:1575.
10. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582.
11. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453.
12. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64.
13. Koster T., Rosendaal E.R., de Ronde H., et al. Venous thrombosis due to poor anticoagulant response to activated protein C Leiden Thrombophilia Study . Lancet. 342:1993;1503.
14. Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med. 330:1994;517.
15. Rosing J., Tans G., Nicolaes G.A.F., et al. Oral contraceptives and venous thrombosis different sensitivities to activated protein C in women using second- and third-generation oral contraceptives . Br J Haematol. 97:1997;233.
16. Sporrong T., Mattsson L.-A., Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progesterone treatment of postmenopausal women. Br J Obstet Gynaecol. 97:1990;939.